How immune responses affect the creation of antibodies from HIV vaccines
Project 1: The impact of innate immune responses on the development of broadly neutralizing antibodies by vaccination
['FUNDING_P01'] · UNIV OF NORTH CAROLINA CHAPEL HILL · NIH-11059130
This study is looking at ways to make HIV vaccines work better by boosting the body's immune response to create special antibodies that can fight different strains of the virus, and it's designed for anyone interested in improving HIV prevention.
Quick facts
| Phase | ['FUNDING_P01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIV OF NORTH CAROLINA CHAPEL HILL (nih funded) |
| Locations | 1 site (CHAPEL HILL, UNITED STATES) |
| Trial ID | NIH-11059130 on ClinicalTrials.gov |
What this research studies
This research investigates how the body's immune responses can be harnessed to improve the effectiveness of HIV vaccines. It focuses on the development of broadly neutralizing antibodies (bNAbs) that can target various strains of the virus. By using specific adjuvants, which are substances that enhance the body's immune response to vaccines, the study aims to identify mechanisms that can boost the production and maturation of these important antibodies. The research involves both animal models and innovative vaccine designs to explore these interactions.
Who could benefit from this research
Good fit: Ideal candidates for this research include adults who are at risk for HIV or those interested in participating in HIV vaccine trials.
Not a fit: Patients who are not at risk for HIV or those who have already been vaccinated against HIV may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective HIV vaccines that provide broader protection against the virus.
How similar studies have performed: Previous studies have shown promise in enhancing antibody responses through the use of adjuvants, indicating that this approach has potential for success.
Where this research is happening
CHAPEL HILL, UNITED STATES
- UNIV OF NORTH CAROLINA CHAPEL HILL — CHAPEL HILL, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: DE PARIS, KRISTINA — UNIV OF NORTH CAROLINA CHAPEL HILL
- Study coordinator: DE PARIS, KRISTINA
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Acquired Immune Deficiency Syndrome Virus, Acquired Immunodeficiency Syndrome Virus